Reports Q1 revenue $194.52M, consensus $206.02M. “This was another strong quarter for Attruby, highlighting the continued durable growth trajectory for use in ATTR-CM by physicians compounding quarter over quarter,” said Matt Outten, Chief Commercial Officer of BridgeBio (BBIO). “Beyond Attruby, we have assembled commercial teams for LGMD2I/R9, ADH1, and achondroplasia, preparing to serve these communities from day one. We have a commercial organization that knows how to launch, how to scale, and how to build, and we are just getting started.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio receives regulatory approval in Brazil for Beyonttra
- BridgeBio price target raised to $102 from $95 at Truist
- Zemansky Reiterates Buy on BridgeBio, Nudges Price Target to $96 on Attruby Edge and Reduced Tafamidis Patent Overhang
- BofA ups BridgeBio price target, cites exclusivity ‘disappointment’ for pullback
- Midday Fly By: OpenAI said to miss targets, Coca-Cola reports Q1 beat